Potential benefit
Finding clinically significant cancer before symptoms develop, when treatment may be more effective. Screening can reduce prostate-cancer deaths in some groups over time, but the size of benefit varies.
PROSTATE CANCER
Understanding PSA, diagnosis, risk and modern treatment.
Prostate cancer develops in the prostate gland. It is one of the most common cancers in men, but its behaviour varies considerably.
Some prostate cancers grow slowly and may never threaten a person’s health. Others can grow or spread more quickly and require treatment.
Modern care depends not simply on whether cancer is present, but on its grade, stage, risk category, molecular characteristics and the individual patient’s circumstances.
Medical Oncologist
Last medically reviewed:
The prostate is a small gland below the bladder and in front of the rectum. It surrounds the urethra, the tube that carries urine out of the body, and contributes fluid to semen. Prostate cancer begins when cells in this gland grow in an uncontrolled way. Most prostate cancers are adenocarcinomas, meaning they develop from gland-forming cells.
Increasing age is an important risk factor. Many cancers remain confined to the prostate for years, while some have biological features that allow faster growth or spread. A small tumour is not automatically harmless, and a cancer diagnosis alone does not tell the whole story.
A diagnosis of prostate cancer does not automatically mean immediate treatment is required. The cancer’s characteristics, overall health and personal priorities all matter.
Early prostate cancer often causes no symptoms. Possible urinary changes include difficulty starting urination, a weak stream, increased frequency, waking at night to pass urine (nocturia), or a feeling that the bladder has not emptied. Blood in urine or semen also needs assessment.
These symptoms commonly have non-cancer causes, especially benign prostate enlargement, inflammation or infection. They cannot diagnose prostate cancer, and having no urinary symptoms does not exclude it.
Advanced disease may sometimes cause persistent bone or back pain, unexplained weight loss, fatigue or difficulty passing urine because of obstruction.
When to seek urgent help: new leg weakness, difficulty walking, numbness around the buttocks or genitals, or new loss of bladder or bowel control—particularly with back pain—may indicate spinal cord or nerve compression. Seek emergency assessment. Inability to pass urine also needs urgent care.
Read more about Warning Signs.
Risk increases with age. A father or brother with prostate cancer, several affected relatives, or diagnosis at a young age in the family can increase risk. In some populations, men of African ancestry have a higher risk of clinically significant disease; individual assessment also considers family history and access to care.
Inherited alterations in genes such as BRCA2, and sometimes BRCA1, HOXB13 or genes associated with Lynch syndrome, may increase susceptibility. A family pattern of prostate, breast, ovarian, pancreatic or related cancers can be relevant, on either side of the family.
Most men with prostate cancer do not have an identifiable inherited cancer syndrome. A genetic counsellor can help interpret a concerning family history. No diet or supplement guarantees prevention; see our broader Prevention guidance for healthy habits.
PSA means prostate-specific antigen. It is a protein made by prostate tissue and measured in a blood test. Both normal prostate cells and prostate-cancer cells can produce it.
A raised PSA does not automatically mean prostate cancer.
PSA can rise with benign prostate enlargement, prostatitis or other inflammation, urinary infection, urinary retention, and recent prostate procedures or manipulation. Recent ejaculation may temporarily affect a result. Some medicines, including finasteride or dutasteride, lower PSA and change how clinicians interpret it.
Screening means testing someone without symptoms. It is a shared decision, with potential benefits and harms.
Finding clinically significant cancer before symptoms develop, when treatment may be more effective. Screening can reduce prostate-cancer deaths in some groups over time, but the size of benefit varies.
False-positive results, anxiety, unnecessary investigations, biopsy complications, and detection of cancers that would never have caused harm. Treating these cancers can cause avoidable urinary, sexual or bowel effects.
There is no single screening age or testing interval that suits everyone. Country-specific guidance, baseline PSA, inherited or familial risk, overall health, life expectancy and preferences all matter. Higher-risk men may need an earlier discussion. Screening is an informed choice, not a compulsory test for every man.
Symptoms require diagnostic assessment rather than waiting for a screening appointment. Explore the general principles of Screening.
An unexpectedly raised PSA is a reason for assessment, not a diagnosis. A practical pathway may include:
Clinicians may consider PSA density (PSA relative to prostate volume), the trend over time, age, prostate size, MRI findings and validated risk calculators. A trend or a single threshold should not be used in isolation to make a treatment decision.
The sequence varies when symptoms or findings need urgent investigation, or when MRI is unavailable or unsuitable. Some people can avoid an immediate biopsy with a clear follow-up plan; others still need biopsy despite a reassuring MRI.
Prostate MRI provides detailed pictures of the gland. Multiparametric MRI combines different types of images to help identify suspicious areas, estimate the likelihood of clinically significant cancer, guide targeted biopsy and assess local tumour extent.
PI-RADS is a standardised way of describing how suspicious an MRI finding looks. Scores run from 1 (very unlikely to represent clinically significant cancer) to 5 (very likely); 3 is an uncertain or equivocal result.
A PI-RADS score is not a cancer stage or a Grade Group. MRI cannot definitively diagnose or exclude every cancer. Its findings need to be considered alongside PSA, clinical risk and the possible need for biopsy.
A definitive diagnosis generally requires prostate tissue to be examined under a microscope. A biopsy takes small cores of tissue using a needle, with appropriate anaesthesia or pain relief.
The pathologist determines whether cancer is present, its type, Gleason score and Grade Group, and how much of the sampled tissue contains cancer. Particular growth patterns can also influence risk assessment.
Bleeding, discomfort, infection and difficulty passing urine are possible complications. Follow the biopsy team’s preparation and aftercare instructions; fever, shaking chills, heavy bleeding or inability to urinate need prompt medical attention. See Understanding Your Cancer Diagnosis.
Grade describes how abnormal the cancer’s gland patterns look under the microscope and helps estimate its likely behaviour. Gleason scoring reports two pattern numbers; the predominant pattern comes first, with the second reflecting another relevant pattern. Modern reports also give a simpler Grade Group from 1 to 5.
| Grade Group | Gleason score |
|---|---|
| 1 | 3 + 3 = 6 |
| 2 | 3 + 4 = 7 |
| 3 | 4 + 3 = 7 |
| 4 | 8 (4 + 4, 3 + 5 or 5 + 3) |
| 5 | 9–10 |
3 + 4 and 4 + 3 are not equivalent. Both add up to 7, but 4 + 3 contains a predominant pattern 4 and generally represents more aggressive disease.
Gleason 6 is the lowest score usually assigned to prostate cancer in contemporary practice. It does not mean “six out of ten” on a simple severity scale.
Grade is only one part of risk assessment. PSA, stage, the amount of cancer in biopsy samples, imaging and other pathological features also matter. A biopsy samples only part of the gland, so later assessment can sometimes change the grade.
Stage describes where the cancer is. In TNM staging, T describes the tumour’s extent in and around the prostate, N describes regional lymph-node involvement, and M describes distant spread.
The cancer appears confined to the prostate.
It extends beyond the prostate, involves nearby structures and/or has reached regional lymph nodes.
It has spread to distant lymph nodes, bones or other organs.
Risk group estimates how likely the disease is to progress or return. Doctors use PSA, Grade Group, clinical stage, tumour extent and imaging to classify disease as low, intermediate or high risk. Intermediate risk may be divided into favourable and unfavourable groups.
Stage and risk group are related but not identical. A cancer still confined to the prostate can be high risk because of its grade or other features. Ask the team to explain both labels.
PSMA means prostate-specific membrane antigen. Many prostate-cancer cells express high levels of this protein. A PSMA PET scan uses a small amount of a radioactive tracer that binds to PSMA, helping reveal deposits in lymph nodes, bone or other organs.
It may be used for staging higher-risk cancer, investigating recurrence after treatment, or assessing eligibility for certain PSMA-targeted treatments. It can sometimes detect disease that is not apparent on conventional CT or bone scans.
Not every newly diagnosed patient needs PSMA PET. Very small deposits and cancers with low PSMA expression can be missed; some non-cancer findings can also show uptake. The result must be interpreted in context, with attention to whether it will change care.
Active surveillance does not mean ignoring cancer.
Not every prostate cancer needs immediate surgery or radiotherapy. Active surveillance may be appropriate for suitable low-risk cancers and selected favourable intermediate-risk cancers, after careful review of grade, tumour extent, imaging and other features.
It is a structured programme that may involve PSA testing, clinical review, MRI, repeat biopsy and other reassessment when appropriate. The aim is to avoid or delay treatment and its side effects while retaining the opportunity for treatment with curative intent if clinically important progression develops.
A PSA change can trigger further assessment; it does not automatically mean treatment must start. Changes in biopsy findings, imaging and the overall risk picture are considered together. Keeping appointments and knowing the follow-up plan are essential.
Some people find living with an untreated cancer emotionally difficult. Discuss these concerns with the team; support and a clear monitoring plan can help.
Curative treatment remains an option. Scheduled tests look for a clinically meaningful change so that treatment can begin if needed.
Main goal: preserve the chance of cure while avoiding or delaying unnecessary treatment.
Care focuses on symptoms and wellbeing, with treatment if problems develop. Routine testing is usually less intensive.
Main goal: symptom control when radical treatment is unlikely to offer meaningful benefit, considering health, frailty, other illnesses, life expectancy and preferences.
This is not a decision based on age alone. Watchful waiting remains active medical care and support, even though eventual curative treatment is not its usual objective.
Options may include active surveillance, radical prostatectomy, external-beam radiotherapy or brachytherapy in appropriate settings. For selected higher-risk disease, radiotherapy is combined with androgen-deprivation therapy (ADT).
There is no universally best treatment. Decisions consider stage and risk group, overall health, life expectancy, existing urinary and sexual function, expected benefit, side effects and patient preferences.
Discussing the case with a multidisciplinary team can help. When both surgery and radiotherapy are reasonable, consultations with the relevant specialists allow a balanced comparison. Ask about the possibility of needing additional treatment later as well as the immediate effects. Read Cancer Treatment Explained.
Radical prostatectomy removes the prostate and usually the seminal vesicles. Nearby lymph nodes may be assessed or removed when the estimated risk makes this appropriate.
Potential effects include urinary leakage or incontinence and erectile dysfunction. Surgery also carries perioperative risks such as bleeding, infection and blood clots. Recovery and long-term effects vary with baseline function, the extent of surgery and other individual factors.
Nerve-sparing may be possible when oncologically appropriate, but does not guarantee preservation of erections. Pelvic-floor rehabilitation and sexual-health support can help. Surgery removes the source of semen, so fertility and sexual changes deserve discussion before treatment.
Open, laparoscopic and robotic approaches are different ways to perform the operation. Robotic surgery is not inherently superior at curing cancer; surgeon experience, careful selection and the quality of care matter.
Radiotherapy damages cancer cells with carefully planned radiation. External-beam treatment is delivered from a machine; brachytherapy places radiation sources within the prostate in suitable patients.
Modern schedules may use fewer sessions with a higher dose per session, called hypofractionation. Stereotactic body radiotherapy (SBRT) is an especially short-course approach for appropriately selected patients. The suitable technique depends on cancer risk, urinary function, anatomy and local expertise.
ADT may accompany radiotherapy, with its duration matched to the disease setting. Potential effects include urinary frequency or irritation, bowel urgency or bleeding, sexual dysfunction and fatigue. Some effects occur during treatment and settle; others can appear or persist later.
Both surgery and radiotherapy can affect quality of life. Compare the likely benefits and effects in the context of existing function and personal priorities.
Many prostate-cancer cells depend on signals from androgens, including testosterone. ADT usually lowers testosterone production, reducing these growth signals. Related medicines can block the androgen receptor or further reduce androgen production.
ADT is most often given with medicines that suppress testicular testosterone production. Less commonly, surgical removal of the testes (orchiectomy) provides permanent suppression. Additional androgen-receptor pathway therapy may be combined with ADT in particular settings.
Possible effects include hot flushes, reduced libido, erectile dysfunction, fatigue, loss of muscle, increased body fat and bone loss. Blood sugar, cholesterol and cardiovascular risk may also be affected. The type and duration of treatment influence the experience.
Monitoring is part of treatment. Discuss an appropriate exercise plan, bone health, blood pressure, weight, blood glucose and lipids, alongside any existing heart disease. Tell the team about troublesome symptoms so that supportive measures can be considered.
High-risk localised or locally advanced prostate cancer often needs more than one treatment. Radiotherapy with ADT is a common approach; modern androgen-receptor pathway treatment may be added in selected situations.
Surgery can be appropriate for selected patients as part of a broader plan, with additional treatment considered according to the findings. Regional lymph-node involvement also affects planning.
The aim, treatment sequence and duration depend on the overall disease picture and health. A multidisciplinary discussion helps coordinate these choices rather than applying one rigid pathway to everyone.
After treatment with curative intent, a confirmed PSA rise meeting the relevant criteria may be called biochemical recurrence. A rising PSA does not necessarily mean that visible metastases are already present.
Interpretation differs after surgery and radiotherapy. After prostate removal, PSA is expected to fall to a very low or undetectable level. After radiotherapy, prostate tissue remains and PSA often falls gradually; a temporary “PSA bounce” can occur without recurrence.
Assessment considers repeat measurements, the speed of PSA rise, original pathology, time since treatment and previous therapy. Imaging, including PSMA PET when appropriate, may help locate disease.
Options can include salvage local treatment, such as radiotherapy after surgery, systemic treatment or monitoring in selected circumstances. A negative scan does not rule out microscopic disease and should not automatically delay otherwise appropriate salvage treatment.
Metastatic prostate cancer that remains responsive to suppression of androgen signalling is called metastatic hormone-sensitive or castration-sensitive prostate cancer. Treatment acts throughout the body to control disease, prolong life and relieve or prevent symptoms.
For many fit patients with metastatic disease, ADT alone is no longer the preferred approach.
Treatment intensification often combines ADT with an androgen-receptor pathway inhibitor, such as an abiraterone-based approach, enzalutamide, apalutamide or darolutamide. Abiraterone is used with an appropriate corticosteroid. The choice depends on the clinical setting, other illnesses, interactions, availability and current guidance.
Selected patients may also receive docetaxel chemotherapy. Triplet treatment combines ADT, an appropriate androgen-receptor pathway inhibitor and docetaxel. Disease burden, timing of metastases, fitness and expected benefit help determine suitability; more treatment is not automatically better for every person.
Biomarker-selected treatment and PSMA-targeted therapy have also entered earlier advanced-disease settings in some jurisdictions. See the DNA-repair and PSMA treatment sections below. Supportive care remains important alongside cancer-directed therapy.
The amount and distribution of metastatic disease can influence treatment. “Low volume” and “high volume” refer to defined patterns used in studies and clinical guidance, rather than simply how well a person feels.
Under the commonly used CHAARTED definition, high-volume disease means spread to an internal organ such as the liver or lung, or at least four bone metastases with at least one outside the spine or pelvis. Lymph-node spread alone does not count as internal-organ spread in this definition. Low-volume disease does not meet these criteria; it can still require intensive systemic treatment.
Selected patients with newly diagnosed low-volume metastatic disease may benefit from radiotherapy directed at the prostate itself, alongside systemic treatment. This does not mean local treatment is appropriate for every metastatic patient, or that systemic therapy can be omitted.
Much of the evidence uses conventional CT and bone-scan definitions. PSMA PET can detect additional small deposits, so the team needs to interpret disease volume in light of the imaging method. Treatments aimed at individual metastases are a separate, evolving question for selected cases.
Cancer is described as castration resistant when it progresses despite testosterone being maintained at castrate levels. Progression may be recognised through PSA, scans or clinical changes; testosterone and the full clinical picture are checked.
Castration resistant does not mean treatment resistant.
Many treatment options may remain. Depending on prior therapy, disease characteristics and biomarkers, these can include androgen-receptor pathway therapy, chemotherapy, PARP-directed treatment, PSMA-targeted radioligand therapy, or a bone-targeted radiopharmaceutical such as radium-223 in an appropriate setting.
Some molecular findings may support other treatments, including immunotherapy in selected cancers. Clinical trials may also be relevant. Treatment sequencing is individualised because benefit from one option can depend on what has already been used.
ADT is usually continued to maintain testosterone suppression while additional treatment is given. Castration resistance can also occur before metastases are visible on conventional imaging; this is a distinct setting with its own management.
Two kinds of testing answer different questions:
Usually uses blood or saliva to look for inherited alterations present throughout the body. A result may affect treatment and can be relevant to relatives.
Examines alterations in the cancer, using tumour tissue or, in selected circumstances, tumour DNA circulating in blood. Many such changes are acquired and are not inherited.
Testing is particularly important in advanced prostate cancer and when a personal or family history suggests inherited risk. It may be appropriate earlier in selected higher-risk disease. Discussing it early can help avoid missing a treatment opportunity.
A tumour result can prompt confirmatory germline testing. An uncertain genetic variant does not automatically justify a targeted drug or testing relatives as if an inherited syndrome were confirmed. Genetic counselling helps explain consent, possible results and family implications.
Tests do not all assess the same genes, and an inadequate sample or negative blood-based result may need further evaluation. Learn more in Cancer Biomarkers & Precision Oncology.
Some prostate cancers have alterations in BRCA1, BRCA2 or other genes involved in homologous recombination repair (HRR), a process that repairs damaged DNA. BRCA2 is particularly important in prostate cancer because it can influence both inherited risk and treatment sensitivity.
PARP inhibitors interfere with another DNA-repair process. In appropriately selected cancers with particular repair defects, this can make it harder for cancer cells to survive. Not every HRR gene predicts the same benefit, and eligibility depends on the exact alteration, disease setting and medicine.
Molecular treatment is no longer only a very-late-line discussion. In December 2025, the US FDA approved niraparib with abiraterone and prednisone for selected BRCA2-mutated metastatic castration-sensitive prostate cancer, alongside continued ADT. PARP-based approaches are also used in selected castration-resistant settings.
These treatments require careful selection and monitoring, including blood counts; fatigue, anaemia and other adverse effects can occur. A US approval does not establish approval, access or suitability in India or another country. The team should check current local guidance and availability.
PSMA PET is an imaging test. PSMA-targeted radioligand therapy is a treatment. A molecule designed to bind PSMA carries a radioactive component to PSMA-expressing cancer deposits.
It is no longer accurate to describe lutetium-177 PSMA treatment only as a very-late-line option. In March 2025, the US FDA expanded its use to selected PSMA-positive metastatic castration-resistant disease after androgen-receptor pathway treatment, when delaying taxane chemotherapy is appropriate.
2026 update: on 31 July 2026, the US FDA approved lutetium-177 PSMA therapy with an androgen-receptor pathway inhibitor for selected PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive disease, the setting previously called metastatic hormone-sensitive prostate cancer. Testosterone suppression is maintained.
Not every prostate cancer is suitable. Eligibility depends on the disease setting, PSMA imaging, previous therapy, kidney and bone-marrow function, overall health, regulatory approval and local availability. These US indications should not be assumed to apply in every country.
Possible effects include dry mouth, fatigue, nausea, low blood counts and kidney toxicity. A specialist nuclear-medicine and oncology team assesses suitability, monitors treatment and gives practical radiation-safety instructions.
Bone care matters for two separate reasons: prostate cancer can spread to bone, and ADT can weaken otherwise healthy bones. Preventing osteoporosis and treating complications of bone metastases are related but different tasks.
Medicines such as bisphosphonates or denosumab require attention to dental health, calcium levels and relevant organ function. Persistent new bone pain should be reported; radiotherapy, pain treatment or other supportive measures can help when needed.
Urinary leakage, erectile dysfunction, reduced desire, hot flushes, fatigue, muscle loss, weight gain and emotional changes can affect everyday life. Some radiotherapy approaches may cause bowel symptoms. These concerns are part of cancer care and deserve a direct conversation.
Pelvic-floor rehabilitation, continence services, sexual-health care, symptom treatments, suitable exercise and nutrition support can help. Include a partner in discussions if desired, and ask about fertility before treatment if it matters to future plans.
Feeling anxious, low or uncertain about body image and intimacy is understandable. Counselling, peer support and clear information can be useful. Supportive and palliative care can improve symptoms and quality of life alongside active cancer treatment; they are not limited to the final stage of illness.
Follow-up is tailored to the original treatment, stage, risk category, PSA results and symptoms. PSA is particularly useful after prostate-cancer treatment, but its meaning depends on whether the prostate remains in place and whether hormone treatment is being used.
Visits can include assessment of urinary, sexual, bowel and emotional health as well as treatment response. People on ADT or other systemic therapy may need testosterone measurements, blood counts, metabolic tests, organ-function tests and bone-health monitoring according to their treatment.
Imaging is guided by the disease setting, symptoms, laboratory results and whether it could change management; it is not automatically needed at every visit. During treatment for advanced disease, planned imaging may be required even if PSA looks reassuring.
Know when the next review is due and who to contact between visits. Report new or worsening symptoms rather than waiting for the next PSA test.
Prostate cancer is not one disease with one treatment. Some cancers can be safely monitored within a structured programme. Others need surgery, radiotherapy, hormone treatment or combinations of therapies.
Modern imaging, molecular testing and targeted treatments are making care increasingly individualised. Understanding PSA, Grade Group, stage, risk category and relevant biomarkers can help patients have more informed discussions with their cancer team.
Cancer Aware provides education—not individual medical advice.
This guide draws on current evidence-based guidance and patient information. Regulatory sources support the recent treatment updates. Recommendations, approvals and access vary by country; reference to an organisation does not imply endorsement.
Sources checked and educational content updated: .
Read about Cancer Aware’s sources and medical review.
This chapter provides general education, not an individual diagnosis, treatment recommendation or prescription. Discuss symptoms, results and care with a qualified healthcare professional. See the Cancer Aware Medical Disclaimer.